Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine.  The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period.  The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA among patients in the study who failed to respond to etanercept.

Psoriasis is an inflammatory disorder characterized by raised, inflamed, red lesions, or plaques, which can cause physical pain.  It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis, which can present in various forms, ranging from mild to severe and disabling. 

"This study provides important comparative efficacy information about the treatment of moderate to severe plaque psoriasis with two biologic agents," said professor Christopher Griffiths, MD, FRCP, University of Manchester, Manchester, UK, and lead trial investigator.  "We observed a substantial proportion of patients achieving high levels of skin clearance with ustekinumab, both through the study's primary endpoint at week 12 and following crossover from etanercept, including in those patients who showed a lack of response to etanercept during the study."

In the comparator study, 68 and 74 percent of patients receiving subcutaneous injections of STELARA (45 mg or 90 mg) at weeks 0 and 4 achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANGELES , July 23, 2014  Researchers from ... with calcium elevates calcium levels too high, ... among other health problems. Women close to ... and vitamin D to prevent diseases such as osteoporosis, ... would recommend that women determine how much calcium they ...
(Date:7/23/2014)... BOSTON , July 23, 2014  The ... CBRX ) will hold a conference call ... for the second quarter ended June 30, 2014. ... July 31, 2014Time: , 8:30 am EDTDial-in numbers: ... (Canada) or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... , July 23, 2014  Cardica, Inc. (Nasdaq: ... for its fiscal fourth quarter and year ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call Details ... at 4:30 p.m. Eastern Time via phone, please dial 866-953-6859 ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
... Evergreen Hospital – one of the region,s leaders in ... gallbladder removal in the Washington and Oregon region on ... a procedure just approved by the FDA. ... two patients – a 66-year-old man and a 33-year-old ...
... March of Dimes announced today that Watson Pharmaceuticals has become ... the March of Dimes number one fundraising event, and will ... the organizations will also work to raise awareness of risk ... participating in March for Babies events around the country as ...
Cached Medicine Technology:Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 2Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 3Watson Partners With March of Dimes to Help Fight Preterm Birth 2
(Date:7/23/2014)... study in East Asian women has identified three genetic ... The research, led by Vanderbilt University investigators, was published ... While breast cancer is one of the most common ... risk factors for the disease have focused on women ... heritage and environmental exposures between East Asian women and ...
(Date:7/23/2014)... July 23, 2014 Five years ago, when ... there were few options for babies diagnosed with a medical ... travel across the country for innovative fetal therapies. Since then, ... Institute to care for their babies in the womb, and ... interventions. , “A number of the babies we see ...
(Date:7/23/2014)... Dennis Thompson HealthDay Reporter , ... with salt is associated with double the risk of heart ... risk skyrockets even higher among those whose diabetes isn,t well-managed, ... people with diabetes who consumed an average of 5.9 grams ... disease than those who consumed, on average, 2.8 grams of ...
(Date:7/23/2014)... San Jose, California (PRWEB) July 23, 2014 ... – Biocompatible materials are biodegradable substances exclusively developed ... to repair or replace diseased body tissues. These ... tissue rejection by the host. Global market for ... driven by factors such as technological advancements and ...
(Date:7/23/2014)... Jose, California (PRWEB) July 23, 2014 ... Packaging plays a vital role in the marketing ... product from damage to influencing customers’ purchase decision. ... brand/product differentiation. Intelligent and efficient packaging provides ample ... to invest in advanced packaging technologies such as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... more evidence that people infected with HIV, the virus that ... as other patients when they undergo kidney transplants. Up ... to HIV patients because of fear that AIDS would quickly ...
... hosting an event on World Aids Day, bringing together some ... future projections for the AIDS pandemic., The panel speakers are ... of Hygiene & Tropical Medicine and former Executive Director of ... Larson, Director of aids2031, an independent consortium set up by ...
... HealthDay Reporter , THURSDAY, Nov. 18 (HealthDay News) ... procedure, can be made more precise by combining a ... Researchers found that a femtosecond laser, used for many ... tissue more cleanly and accurately than manual cataract surgery, ...
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- Using the ... that doctors, prescribing patterns vary across the country in response ... Administration. The result is that patients may be ... live, the researchers said. "We were looking at the ...
... a cardiomyopathy about which little is fully understood, is ... according to a study to be presented Nov. 17 ... in Chicago. The researchers also will report that advanced ... to progress over time in patients with LVNC. ...
... international, multi-center study has revealed the discovery of a novel ... form of eye cancer. Researchers have isolated an oncogene called ... than 40 percent of tumor samples taken from patients with ... November 17, 2010 in the New England Journal of ...
Cached Medicine News:Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:AIDS: Taking a long-term view 2Health News:Study Reports More Precise Way to Remove Cataracts 2Health News:Study Reports More Precise Way to Remove Cataracts 3Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3Health News:Cardiac MR sheds light on obscure heart muscle condition 2Health News:Novel genetic mutation that causes the most common form of eye cancer discovered 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: